Mother and child with doctor. Image credit: Canva
Neuroblastoma is a type of cancer that causes tumors in nerves. It affects mainly infants and toddlers, and it causes about 15 percent of cancer-related deaths in children.
A clinical trial led by Rosa Nguyen, M.D., Ph.D., in the Pediatric Oncology Branch is researching whether adding an immunotherapy, rhIL-15, to three standard treatments will improve treatment results for neuroblastoma that has come back or not responded to treatment in children and young adults.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
ClinicalTrials.gov ID: NCT06995872
Trial ID: IRB001842
Who to Contact for Questions:
Email NCI Medical Oncology Referral Office
Call 888-624-1937
Official Title: Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
